449 related articles for article (PubMed ID: 7911403)
1. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension.
Hilleman DE; Mohiuddin SM; Lucas BD; Stading JA; Stoysich AM; Ryschon K
Clin Ther; 1994; 16(1):88-102; discussion 87. PubMed ID: 7911403
[TBL] [Abstract][Full Text] [Related]
2. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
Hilleman DE; Reyes AP; Wurdeman RL; Faulkner M
J Hum Hypertens; 2001 Aug; 15(8):559-65. PubMed ID: 11494095
[TBL] [Abstract][Full Text] [Related]
4. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory?
Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI
Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive drug prescription trends at the primary health care centres in Bahrain.
Jassim al Khaja KA; Sequeira RP; Wahab AW; Mathur VS
Pharmacoepidemiol Drug Saf; 2001 May; 10(3):219-27. PubMed ID: 11501335
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of different pharmacological treatment strategies in elderly hypertensives.
Linjer E; Hedner T; Jönsson B; Ekbom T; Lindholm LH; Dahlöf B; de Faire U; Scherstén B;
Blood Press; 2005; 14(2):107-13. PubMed ID: 16036488
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive pharmacotherapy in a developing economy: pattern, acquisition costs and conformity to international guidelines in a tertiary-care setting.
Amira CO; Okubadejo NU
J Hum Hypertens; 2006 Nov; 20(11):894-7. PubMed ID: 16915299
[No Abstract] [Full Text] [Related]
8. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
[TBL] [Abstract][Full Text] [Related]
9. [German Hypertension League update. What does the ALLHAT Study really mean?].
MMW Fortschr Med; 2003 Jun; 145(23):45-6. PubMed ID: 12854226
[No Abstract] [Full Text] [Related]
10. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
[TBL] [Abstract][Full Text] [Related]
11. The need for evidence in hypertension management: historical perspective.
Moawad MA
Ann Saudi Med; 2005; 25(5):367-74. PubMed ID: 16270757
[TBL] [Abstract][Full Text] [Related]
12. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
[TBL] [Abstract][Full Text] [Related]
14. Treating hypertension. Are the right drugs given to the right patients?
Beaulieu MD; Dufresne L; LeBlanc D
Can Fam Physician; 1998 Feb; 44():294-8, 301-2. PubMed ID: 9512833
[TBL] [Abstract][Full Text] [Related]
15. [Fully possible to reduce the costs of hypertension treatment].
Wettermark B; Angman A; Hjemdahl P
Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
[No Abstract] [Full Text] [Related]
16. [Are the newer antihypertensive agents better and more effective than diuretics?].
Landmark K
Tidsskr Nor Laegeforen; 2001 Feb; 121(6):701-5. PubMed ID: 11293353
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
18. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure.
Schelleman H; Klungel OH; Witteman JC; Hofman A; van Duijn CM; de Boer A; Stricker BH
Eur J Hum Genet; 2006 Jul; 14(7):860-6. PubMed ID: 16724011
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
Johannesson M
J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
